Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CVT And Gilead Look To Lock Out Astellas With Planned Merger

Executive Summary

Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion

You may also be interested in...

Gilead Springs Further Into Oncology With Calistoga Acquisition

Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.

Ramius' Hostile Bid For Cypress Bioscience Has Unusual Twist

The hedge fund operator offers $154 million after Cypress' unpopular licensing of an anti-psychotic drug. But Ramius might want to share the upside on the drug after all.

Gilead Recruits Hepatitis C Specialist McHutchison In Show Of Commitment

Appointment of leading hepatitis C expert from Duke to senior VP-liver disease therapeutics reaffirms Gilead's commitment to expanding into hepatitis C.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts